Gene therapy research firm Intrexon has been served with a class action lawsuit in Delaware by shareholders who oppose the company’s acquisition by GenVec, citing a lack of advantages and an inaccurate SEC registration statement.
Gene therapy research firm GenVec has been served with a class action lawsuit in Delaware by shareholders who oppose the company’s acquisition by Intrexon, citing a lack of advantages and an inaccurate SEC registration statement.